BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:44 PM
 | 
Nov 19, 2008
 |  BC Extra  |  Top Story

Amgen, Millennium suspend motesanib trial

Amgen (NASDAQ:AMGN) and partner Millennium said they temporarily suspended enrollment in the Phase III MONET1 trial of motesanib ( AMG 706) as first-line therapy for advanced non-small cell lung cancer (NSCLC). The decision was based on a recommendation from the study's independent DMC, which observed higher early mortality rates in the...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >